EDEM1 and EDEM2 were slightly increased in prostate cancer patients in two out of five cohorts, suggesting that they may play some role in ERAD in prostate cancer; however, their expression was in no way associated with disease-free progression. This evidence concerns the gene EDEM1 and prostate carcinoma.